WASHINGTON (AP) — Drugmaker Sarepta Therapeutics said late Friday it won’t comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of a third patient receiving one of its treatments for muscular dystrophy. The highly unusual move is a latest in a string of events that have hammered the …
Read More »Cyptea Daily News
Breaking News
- Texas Gerrymandering Could Backfire Badly
- Cram Fire Grows to Largest Wildfire of the Year So Far in U.S. – The New York Times
- Derecho, severe weather pattern now over the heart of the Great Lakes, Michigan
- Travelers to the U.S. must pay a new $250 ‘visa integrity fee’ — what to know
- Baltimore overdoses may be linked to new drug – The Washington Post